These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Histone deacetylase inhibitors in cancer therapy. Lane AA; Chabner BA J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124 [TBL] [Abstract][Full Text] [Related]
12. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Kaler P; Sasazuki T; Shirasawa S; Augenlicht L; Klampfer L Exp Cell Res; 2008 Apr; 314(7):1507-18. PubMed ID: 18314102 [TBL] [Abstract][Full Text] [Related]
13. Acetylation of proteins as novel target for antitumor therapy: review article. Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351 [TBL] [Abstract][Full Text] [Related]
14. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Rahman I; Marwick J; Kirkham P Biochem Pharmacol; 2004 Sep; 68(6):1255-67. PubMed ID: 15313424 [TBL] [Abstract][Full Text] [Related]
15. Role of histone deacetylase inhibitors in the treatment of cancer (Review). Mei S; Ho AD; Mahlknecht U Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685 [TBL] [Abstract][Full Text] [Related]
16. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Savickiene J; Borutinskaite VV; Treigyte G; Magnusson KE; Navakauskiene R Eur J Pharmacol; 2006 Nov; 549(1-3):9-18. PubMed ID: 16978604 [TBL] [Abstract][Full Text] [Related]